Celltrion targets KRW 600 billion Q4 operating profit: meaning for Celltrion stock
Published on 10/20/2026 at 04:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSProfit plan and stock context
- On October 19, 2026, Celltrion targeted at least KRW 600 billion in fourth-quarter operating profit.
- Third-quarter operating margin reached 34 percent on October 12, 2026.
- Celltrion stock was last at KRW 196,100 on KRX on October 20, 2026 at 11:06 a.m. KST.
Celltrion (ISIN KR7068270008) is targeting at least KRW 600 billion in fourth-quarter operating profit after meeting its first three quarterly goals, according to Celltrion in a shareholder letter dated October 19, 2026. The company also reported third-quarter revenue of KRW 1.5 trillion and operating profit of KRW 510 billion on October 12, 2026.
Three milestones shape the year
Celltrion's October 12, 2026 results showed third-quarter revenue up 45.8 percent year on year to KRW 1.5 trillion, while operating profit rose 69.2 percent to KRW 510 billion, according to Celltrion. On October 19, 2026, the company set its fourth-quarter operating profit target at KRW 600 billion or more and said about 80 executives and sales leaders had reviewed global performance. On October 20, 2026, Celltrion stock was last at KRW 196,100 on the Korea Exchange at 11:06 a.m. KST.
What does the Q4 target mean?
The target implies operating profit growth of 17.65 percent from the KRW 510 billion achieved in the third quarter. Seoul Economic Daily reported on October 20, 2026 that Celltrion expects at least KRW 600 billion in fourth-quarter operating profit and plans to maintain shareholder returns through dividends or treasury-share cancellations. The earnings structure is also becoming more profitable: the third-quarter operating margin reached 34 percent, up 4.7 percentage points from a year earlier.
Stock valuation remains wide
Celltrion's market capitalization was KRW 44.8 trillion as of October 20, 2026. Its 52-week range was KRW 158,500.00 to KRW 239,047.62, placing the latest KRW 196,100 quote between the two reference points. The company is using higher-margin follow-on biosimilars, cost improvements and the U.S. launch of Omlyclo to support the fourth-quarter plan.
KRX quote and investor context
Celltrion was last at KRW 196,100 on the Korea Exchange on October 20, 2026 at 11:06 a.m. KST. The company trades under ticker 068270 in the KOSPI market and operates in biotechnology.
Celltrion stock key facts
- Company: Celltrion, Inc.
- ISIN: KR7068270008
- Ticker: 068270
- Primary exchange: Korea Exchange
- Price Korea Exchange (as of October 20, 2026, 11:06 a.m. KST): KRW 196,100.00
- Market capitalization: KRW 44.8 trillion (as of October 20, 2026)
- 52-week range: KRW 158,500.00-239,047.62 (as of October 20, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: KOSPI
Market context: Market report KOSPI.
